DekaBank Deutsche Girozentrale - ULTRAGENYX PHARMACEUTICAL IN ownership

ULTRAGENYX PHARMACEUTICAL IN's ticker is RARE and the CUSIP is 90400D108. A total of 237 filers reported holding ULTRAGENYX PHARMACEUTICAL IN in Q1 2022. The put-call ratio across all filers is 2.14 and the average weighting 0.1%.

Quarter-by-quarter ownership
DekaBank Deutsche Girozentrale ownership history of ULTRAGENYX PHARMACEUTICAL IN
ValueSharesWeighting
Q3 2023$1,406
-24.7%
40,0000.0%0.00%
-25.0%
Q2 2023$1,868
+61.9%
40,000
+33.3%
0.00%
+33.3%
Q1 2023$1,154
-14.6%
30,0000.0%0.00%
-25.0%
Q4 2022$1,351
-99.9%
30,0000.0%0.00%0.0%
Q3 2022$1,210,000
-49.7%
30,000
-25.7%
0.00%
-42.9%
Q2 2022$2,405,000
-18.5%
40,360
-2.4%
0.01%0.0%
Q1 2022$2,951,000
-13.8%
41,3600.0%0.01%
-12.5%
Q4 2021$3,425,000
+13.6%
41,360
+18.5%
0.01%0.0%
Q3 2021$3,014,000
+85.6%
34,910
+106.4%
0.01%
+60.0%
Q2 2021$1,624,000
-14.4%
16,9100.0%0.01%
-16.7%
Q1 2021$1,898,000
-23.3%
16,9100.0%0.01%
-33.3%
Q4 2020$2,475,000
+58.9%
16,910
-8.3%
0.01%
+28.6%
Q3 2020$1,558,000
+45.2%
18,450
-26.9%
0.01%0.0%
Q3 2019$1,073,000
-79.2%
25,250
-69.6%
0.01%
-73.1%
Q2 2019$5,151,000
+513.2%
83,000
+315.0%
0.03%
+333.3%
Q4 2018$840,000
-59.3%
20,000
-51.1%
0.01%
-57.1%
Q1 2018$2,062,000
+44.2%
40,920
+75.5%
0.01%
+27.3%
Q4 2017$1,430,0000.0%23,3200.0%0.01%0.0%
Q3 2017$1,430,000
-0.9%
23,3200.0%0.01%0.0%
Q2 2017$1,443,000
-8.0%
23,3200.0%0.01%
-21.4%
Q1 2017$1,569,000
-20.8%
23,320
-16.2%
0.01%
-33.3%
Q4 2016$1,981,000
-16.8%
27,820
-19.9%
0.02%
-19.2%
Q3 2016$2,381,000
-19.9%
34,720
-41.9%
0.03%
-23.5%
Q2 2016$2,971,000
+180.0%
59,720
+222.5%
0.03%
+161.5%
Q1 2016$1,061,000
-52.3%
18,520
-5.8%
0.01%
-48.0%
Q4 2015$2,223,000
+27.8%
19,670
+8.9%
0.02%
+19.0%
Q3 2015$1,739,000
-0.1%
18,060
+6.2%
0.02%0.0%
Q2 2015$1,741,000
+71.0%
17,000
+3.7%
0.02%
+61.5%
Q1 2015$1,018,00016,4000.01%
Other shareholders
ULTRAGENYX PHARMACEUTICAL IN shareholders Q1 2022
NameSharesValueWeighting ↓
First Light Asset Management, LLC 213,887$29,608,0002.19%
Rock Springs Capital Management LP 566,500$78,421,0001.66%
FEDERATED HERMES, INC. 4,280,528$592,554,0001.21%
AtonRa Partners 17,646$2,443,0001.20%
EMERALD MUTUAL FUND ADVISERS TRUST 218,390$30,232,0001.05%
EMERALD ADVISERS, LLC 226,875$31,406,0001.04%
Atika Capital Management LLC 89,000$12,319,0000.96%
Capital Impact Advisors, LLC 25,582$3,541,0000.87%
JGP Global Gestao de Recursos Ltda. 1,586$220,0000.83%
CAPITAL INTERNATIONAL LTD /CA/ 79,742$11,039,0000.64%
View complete list of ULTRAGENYX PHARMACEUTICAL IN shareholders